Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 370 IN PLASTIC CONTAINER versus MD 76R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 370 IN PLASTIC CONTAINER versus MD 76R.
IOPAMIDOL-370 IN PLASTIC CONTAINER vs MD-76R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic, low-osmolality radiocontrast agent that attenuates X-rays by blocking their passage, thereby enhancing the contrast of vascular structures and tissues during imaging. It does not have a specific molecular target but relies on its iodine content for radiopacity.
MD-76R is a radiopaque contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast of blood vessels and tissues during radiographic procedures. It functions by increasing the absorption of X-rays in areas where it is present, allowing for visualization of vascular structures and organ perfusion.
Intravenous: 0.5-2 mL/kg (185-740 mg iodine/kg) as a single dose; repeated doses may be administered up to a total of 5 mL/kg (1850 mg iodine/kg) within a 24-hour period.
2–4 mL/kg intravenously, maximum 150 mL per procedure.
None Documented
None Documented
Terminal half-life 1.5–2 hours in normal renal function; prolonged to 4–12 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life 1-2 hours; prolonged in renal impairment.
Renal: >90% unchanged by glomerular filtration within 24–48 hours; biliary/fecal: <2%.
Primarily renal; 95% eliminated unchanged in urine within 24 hours; <1% fecal.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent